These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 8854508)

  • 21. Pharmaceuticals and medical devices: business practices.
    Steiner DJ
    Issue Brief Health Policy Track Serv; 2013 Dec; ():1-36. PubMed ID: 24482889
    [No Abstract]   [Full Text] [Related]  

  • 22. When Does FDAMA Section 114 Apply? Ten Case Studies.
    Neumann PJ; Saret CJ
    Value Health; 2015 Jul; 18(5):682-9. PubMed ID: 26297097
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmaceuticals and medical devices: FDA oversight.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2009 Jan; ():1-28. PubMed ID: 19297718
    [No Abstract]   [Full Text] [Related]  

  • 24. A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction.
    Kalish SC; Gurwitz JH; Krumholz HM; Avorn J
    J Gen Intern Med; 1995 Jun; 10(6):321-30. PubMed ID: 7562123
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Examining the link between price regulation and pharmaceutical R&D investment.
    Vernon JA
    Health Econ; 2005 Jan; 14(1):1-16. PubMed ID: 15386673
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The FDA's regulation of health economic information.
    Neumann PJ; Claxton K; Weinstein MC
    Health Aff (Millwood); 2000; 19(5):129-37. PubMed ID: 10992660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Will lower drug prices jeopardize drug research? A policy fact sheet.
    Light DW; Lexchin J
    Am J Bioeth; 2004; 4(1):W1-4. PubMed ID: 15035915
    [No Abstract]   [Full Text] [Related]  

  • 28. Potential stifling effects of pharmaco-economics and regulatory policies.
    Data JL
    Am J Cardiol; 1998 Apr; 81(8A):34F-35F. PubMed ID: 9604904
    [No Abstract]   [Full Text] [Related]  

  • 29. An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase.
    Kent DM; Hayward RA; Griffith JL; Vijan S; Beshansky JR; Califf RM; Selker HP
    Am J Med; 2002 Aug; 113(2):104-11. PubMed ID: 12133748
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of thrombolytics: a simplified model.
    Apikoğlu Rabuş S; Izzettin FV; Sancar M; Rabuş MB; Kirma C; Yakut C
    Pharm World Sci; 2005 Jun; 27(3):243-8. PubMed ID: 16096895
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug company advertising in medical journals about the health-economic advantages of their products for 2000-2006 versus 1990-1999.
    Palmer JA; Timm AR; Neumann PJ
    J Manag Care Pharm; 2008 Oct; 14(8):749-55. PubMed ID: 18983204
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The 21st Century Cures Act: pharmacoeconomic boon or bane?
    Mendoza RL
    J Med Econ; 2017 Apr; 20(4):315-317. PubMed ID: 28092219
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Good research practices for measuring drug costs in cost-effectiveness analyses: Medicare, Medicaid and other US government payers perspectives: the ISPOR Drug Cost Task Force report--Part IV.
    Mullins CD; Seal B; Seoane-Vazquez E; Sankaranarayanan J; Asche CV; Jayadevappa R; Lee WC; Romanus DK; Wang J; Hay JW; Smeeding J
    Value Health; 2010; 13(1):18-24. PubMed ID: 19807903
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FDA actions against misleading or unsubstantiated economic and quality-of-life promotional claims: an analysis of warning letters and notices of violation.
    Stewart KA; Neumann PJ
    Value Health; 2002; 5(5):390-7. PubMed ID: 12201856
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmaceuticals and medical devices: Medicare Part D. Issue brief.
    Steiner DJ
    Issue Brief Health Policy Track Serv; 2012 Dec; ():1-32. PubMed ID: 23297447
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharmaceuticals and medical devices: FDA oversight. End-of-year issue brief.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2008 Jan; ():1-18. PubMed ID: 18345557
    [No Abstract]   [Full Text] [Related]  

  • 38. Pharmacoeconomics comes of age?
    Walley T; Breckenridge A
    Clin Pharmacol Ther; 2008 Aug; 84(2):279-80. PubMed ID: 18563057
    [TBL] [Abstract][Full Text] [Related]  

  • 39. How to improve pharmacoeconomic data generalisability between different countries.
    Li SC
    Expert Opin Pharmacother; 2007 Jul; 8(10):1409-13. PubMed ID: 17661723
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmaceuticals and medical devices: business practices.
    ; Steiner DJ
    Issue Brief Health Policy Track Serv; 2012 Jan; ():1-35. PubMed ID: 22423396
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.